Regeneration of Knee and Ankle Cartilage from Autologous Cartilage Mini-grafts (from the Patient's Own Cells)
Launched by VANARIX SA · Mar 19, 2025
Trial Information
Current as of April 23, 2025
Active, not recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Key inclusion criteria:
- • Cartilage focal lesion(s) ≥ 1.5 cm2 and ≤ 10 cm2
- • ICRS grade 3 or 4
- • Pain for 3 months or more
- • Aged over 18 years
- • Key exclusion criteria
- • Inability to undergo MRI
- • Cartilage specific surgery within 12 months from baseline
- • Cartilage therapeutic injection within 3 months from baseline
- • Radiologically apparent degenerative joint disease (K\&L grade \>1)
- • Chronic inflammatory arthritis and/or infectious arthritis
About Vanarix Sa
Vanarix SA is a clinical research organization dedicated to advancing innovative healthcare solutions through rigorous clinical trials. With a focus on developing cutting-edge therapies and medical interventions, Vanarix SA collaborates with pharmaceutical companies, biotechnology firms, and academic institutions to bring new treatments to market. The organization prides itself on its commitment to scientific integrity, patient safety, and regulatory compliance, ensuring that all trials are conducted to the highest ethical standards. Through its expertise in trial design, patient recruitment, and data management, Vanarix SA plays a pivotal role in transforming scientific discoveries into effective healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Geneva, , Switzerland
Lugano, Ticino, Switzerland
Geneva, , Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Related Blog Entries
View all
